UroGen Pharma Ltd. Payments of Stock Issuance Costs
UroGen Pharma Ltd. (URGN) reported Payments of Stock Issuance Costs of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-14.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2024-03-14
- UroGen Pharma Ltd. payments of stock issuance costs for the quarter ending 2023-12-31 was $0.00.
- UroGen Pharma Ltd. payments of stock issuance costs for the quarter ending 2023-09-30 was $0.00, a 100.00% decline year-over-year.
- UroGen Pharma Ltd. payments of stock issuance costs for the quarter ending 2023-06-30 was $0.00, a 100.00% decline year-over-year.
- UroGen Pharma Ltd. payments of stock issuance costs for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- UroGen Pharma Ltd. payments of stock issuance costs for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- UroGen Pharma Ltd. payments of stock issuance costs for fiscal 2022 was $160.00K, a 11.11% increase from fiscal 2021.
- UroGen Pharma Ltd. payments of stock issuance costs for fiscal 2021 was $144.00K, a 118.18% increase from fiscal 2020.
- UroGen Pharma Ltd. payments of stock issuance costs for fiscal 2020 was $66.00K, a 13.16% decline from fiscal 2019.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month | Payments of Stock Issuance Costs 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $0.00 derived: sum of 3 quarters · filed 2024-03-14 | $0.00 10-K · filed 2024-03-14 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 derived: sum of 2 quarters · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | $0.00 derived: sum of 4 quarters · filed 2024-03-14 |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $0.00 10-Q · filed 2023-08-10 | $0.00 derived: sum of 3 quarters · filed 2024-03-14 | $16.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | $0.00 derived: sum of 2 quarters · filed 2024-03-14 | $16.00K derived: sum of 3 quarters · filed 2024-03-14 | $71.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $16.00K derived: sum of 2 quarters · filed 2024-03-14 | $71.00K derived: sum of 3 quarters · filed 2024-03-14 | $160.00K 10-K · filed 2024-03-14 |
| 2022-09-30 | $16.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $71.00K derived: sum of 2 quarters · filed 2023-11-14 | $160.00K 10-Q · filed 2023-11-14 | $177.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | $55.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $144.00K 10-Q · filed 2023-08-10 | $161.00K derived: sum of 3 quarters · filed 2023-08-10 | $277.00K derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $89.00K 10-Q · filed 2023-05-11 | $106.00K derived: sum of 2 quarters · filed 2023-05-11 | $222.00K derived: sum of 3 quarters · filed 2023-05-11 | $233.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $17.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $133.00K derived: sum of 2 quarters · filed 2023-03-24 | $144.00K derived: sum of 3 quarters · filed 2023-03-24 | $144.00K 10-K · filed 2023-03-24 |
| 2021-09-30 | $116.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $127.00K derived: sum of 2 quarters · filed 2022-11-10 | $127.00K 10-Q · filed 2022-11-10 | $138.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $11.00K 10-Q · filed 2022-08-11 | $22.00K derived: sum of 3 quarters · filed 2022-08-11 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 | $11.00K derived: sum of 2 quarters · filed 2022-05-10 | ||
| 2020-12-31 | $11.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-21 | $66.00K 10-K · filed 2022-03-21 | ||
| 2020-09-30 | $55.00K 10-Q · filed 2021-11-15 | |||
| 2020-03-31 | $203.00K 10-Q · filed 2021-05-13 | |||
| 2019-12-31 | $76.00K 10-K · filed 2021-03-18 | |||
| 2017-03-31 | $112.00K 6-K · filed 2018-05-15 | |||
| 2016-12-31 | $579.00K 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |